TAS-102 (trifluridine/tipiracil; Lonsurf) extended overall survival (OS) in previously treated patients with metastatic gastric cancer, according to findings from the phase III TAGS trial.
The 1-year OS rate with TAS-102 was 27% compared with 18% with placebo. This benefit was observed across all subgroups in the trial, including those with KRAS mutations and across all geographic regions. Additionally, patients treated with prior regorafenib (Stivarga) experienced responses to TAS-102.
- Bando H, Doi T, Muro K, et al. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer. 2016;62:46-53. doi: 10.1016/j.ejca.2016.04.009.
- Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. NEJM. 2015;372:1909-1919.
... to read the full story